Equine infectious anemia virus envelope glycoprotein gp90 (gp90)

The Equine infectious anemia virus (EIAV) envelope glycoprotein gp90 is the surface (SU) subunit of the viral envelope protein complex, produced by the proteolytic cleavage of the gp135/gp150 precursor (UniProt: P03322). It is the primary determinant of viral tropism, mediating attachment to the host cell receptor, Equine Lentivirus Receptor 1 (ELR1), which is a member of the tumor necrosis factor receptor (TNFR) superfamily (PMID: 11435591). gp90 is characterized by a high degree of glycosylation and the presence of multiple hypervariable regions (V1-V11) that undergo rapid evolution under host immune pressure, allowing the virus to persist indefinitely in equids (PMID: 15141007). As the principal target for neutralizing antibodies, gp90 is the central focus of vaccine research, although its extreme sequence plasticity presents a major hurdle for developing broadly protective immunity (PMID: 10666351). While no small-molecule inhibitors are currently approved for clinical use against this target, it remains a critical component in diagnostic assays and the development of experimental attenuated live vaccines. Understanding the structural transitions of gp90 during receptor binding is essential for designing interventions to control Equine Infectious Anemia, a disease characterized by recurring cycles of fever, anemia, and weight loss.

Other names

Surface glycoprotein gp90SU proteinEIAV gp90Envelope surface subunit gp90gp90 SU

Neutralization of viral entry by blocking the interaction between gp90 and the host cell receptor ELR1 or preventing subsequent conformational changes required for fusion.